Navigation Links
B. Braun Large Volume Heparin Infusion Solutions Now Available
Date:7/12/2010

BETHLEHEM, Pa., July 12 /PRNewswire/ -- B. Braun Medical Inc. (B. Braun) announced today the availability of large volume heparin infusion solutions.

(Logo:  http://photos.prnewswire.com/prnh/20081022/NYW008LOGO )

(Logo:  http://www.newscom.com/cgi-bin/prnh/20081022/NYW008LOGO )

Based on the new United States Pharmacopeia (USP) standards for heparin products released by the U.S. Food and Drug Administration (FDA) in October 2009, changes to B. Braun's large volume heparin IV solutions include a modification of the reference standard for the drug's unit dose.

The following heparin infusion solutions are now available from B. Braun without restriction:

  • P5671, Heparin Sodium (40 U/mL) in 5% Dextrose Injection (500 mL EXCEL® Plastic Container)
  • P5771, Heparin Sodium (50 U/mL) in 5% Dextrose Injection (500 mL EXCEL® Plastic Container)
  • P5872, Heparin Sodium (100 U/mL) in 5% Dextrose Injection (250 mL EXCEL® Plastic Container)

In addition, the following heparin infusion solutions remain available on allocation:

  • P8721, Heparin Sodium (2 U/mL) in 0.9% Sodium Chloride Injection (500 mL EXCEL® Plastic Container)

Customer Service (800-227-2862) and Clinical & Technical Support (800-854-6851) teams are available to answer any questions related to availability or product use.

About B. Braun

B. Braun is a leading manufacturer of infusion therapy and pain management products with an environmentally-friendly focus. Guided by the company's "Sharing Expertise®" philosophy, B. Braun addresses the critical issues of infection prevention, medication safety and environmental responsibility by promoting best practices that help clinicians reduce medication errors, prevent healthcare-acquired infections (HAIs) and achieve sustainability objectives.

Consistently recognized by Frost & Sullivan and KLAS for its medical technology and support services, B. Braun employees share their knowledge with colleagues and customers to improve working processes in hospitals and medical practices and to enhance the safety of patients and healthcare professionals. For more information, call 800-227-2862, email us at inquiry.us@bbraun.com or visit B. Braun at www.bbraunusa.com.


'/>"/>
SOURCE B. Braun Medical Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. B. Braun Medical Inc. to Demonstrate Infusion Systems Technologies at HIMSS 2009 Interoperability Showcase
2. B. Braun Awarded Contract With HealthTrust Purchasing Group to Provide Pain Management Solutions
3. B. Braun and Amerinet Sign to Expand Infusion Therapy Offerings
4. MEDRAD and B. Braun Melsungen AG Collaborate to Promote Breakthrough Medical Treatment for Cardiovascular Disease
5. B. Braun Introduces WHIN(R) Safe Huber Needle
6. B. Braun Infusion Systems Complete Interoperability Test for HIMSS10 Interoperability Showcase
7. B. Braun Renal Therapies Division Announces Availability of Adimea
8. FDA Approves Cefepime for Use In B. Brauns DUPLEX(R) System
9. Health Robotics Re-Acquires CytoCares European Rights from B. Braun Melsungen AG for Undisclosed Consideration
10. New Technology Center Increases B. Brauns Infusion Pump Capacity
11. Georgia Reproductive Specialists Participates in Largest-Ever In Vitro Fertilization Clinical Trial in the World
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... Wound care devices and products are used ... The industry mainly consists of establishments engaged in manufacturing ... wounds caused by mechanical, chemical, thermal, and radiogenic trauma; ... diabetes, skin related diseases, immunological diseases, and other chronic ... the largest region in the wound care devices market ...
(Date:3/29/2017)... YORK , March 29, 2017 Global intravenous ... US$ 3 billion by 2021, growing at a CAGR of ... iron prescribed by a doctor to treat anemia or other ... iron level in the body. However, in some cases, oral ... the body and intravenous (IV) iron therapy comes into the ...
(Date:3/29/2017)... 2017  Novartis announced today that the US ... company,s Biologics License Application (BLA) filing and granted ... antigen receptor T cell (CAR-T) therapy, in relapsed ... with B-cell acute lymphoblastic leukemia (ALL). This is ... CAR-T. The priority review designation is expected to ...
Breaking Medicine Technology:
(Date:3/29/2017)... CT (PRWEB) , ... March 29, 2017 , ... HealthCareMandA.com ... —on Thursday, April 20, 2017, at 1:00 PM ET. A recording of the webinar ... the Interactive Webinar Series. , Home health and hospice companies are still popular targets ...
(Date:3/29/2017)... ... March 29, 2017 , ... Immunotherapy has emerged as one ... cancers and is touted to be the next revolution in our fight against this ... in the form of immune checkpoint inhibitors such as PD-1 and PD-L1 inhibitors. , ...
(Date:3/29/2017)... PA (PRWEB) , ... March ... ... eastern suburbs and South Hills of Pittsburgh now have easier access to ... Pennsylvania only by Allegheny Health Network (AHN). Orthopaedic surgeons at Forbes Hospital ...
(Date:3/29/2017)... ... ... The Wharton School of the University of Pennsylvania is pleased to announce that ... gift to establish the Ken Moelis and Julie Taffet Moelis Advance Access Program ... for highly-qualified Penn undergraduates whose academic and career interests expand traditional notions of business ...
(Date:3/29/2017)... ... March 29, 2017 , ... VisualSP has helped over 1.5 million SharePoint ... option for on-premises installation of its Help System for SharePoint was at the farm ... into the entire tenant. , The company recently released a modified version of ...
Breaking Medicine News(10 mins):